Miracle Medical is launching MIRACLEJEX™ needle-free injection systems and ampoules worldwide in mid-2017.

MIRACLEJEX™ products are to be offered at very attractive distribution prices to be easily accessible and affordable to end users. The expected initial production output is 10-12 million consumables per month.

Miracle Medical is keen to engage with regional distributors, medical/healthcare groups and associations for diabetic care who support the adoption of needle-free injection of medication, especially for chronic disease management. Contact Miracle Medical for more details.

For doctors and other medical practitioners who wish to incorporate MIRACLEJEX™ into novel treatment plans or procedures, please contact Miracle Medical.

Upcoming development
Under the leadership of technoprenuer Dr. Chuang P.D., Miracle Medical is launching several new injector systems in 2017. Aside from the standard handheld manually fired injectors, new features include auto-pressure sensing and firing modes (PerfectShot™ Technology), automatic reset injectors and also “smart” injector models featuring user identification and increased device security.

Manufacturing capability
Miracle Medical has invested into the manufacture of its own MIRACLEJEX™ ampoules, with manufacturing capabilities in a large cleanroom in Singapore and the Design and Development of a high-speed syringe assembly system. A new continuous inline assembly technology allows production rates to keep up with market demand. All MIRACLEJEX™ products will be FDA 510K and CE certified.

Development work on a new high speed syringe assembly system is completed and put into manufacture use. This new system is capable of fully automatic assembly of 0.3ml and 0.5ml diabetic syringes at high production rates.

The new MIRACLEJEX™ comes in packaging configurations compatible for both ETO and Gamma sterilization. Miracle Medical is also developing the use of new polycarbonates for ampoules, along with new production and packaging solutions (i.e. bulk packaging) reducing the overall cost to consumers. Contact us to find out more.